U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H38O5
Molecular Weight 418.5662
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SIMVASTATIN

SMILES

[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(=O)O3)OC(=O)C(C)(C)CC

InChI

InChIKey=RYMZZMVNJRMUDD-HGQWONQESA-N
InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

HIDE SMILES / InChI
Molecular Formula C25H38O5
Molecular Weight 418.5662
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/simvastatin.html http://www.rxlist.com/zocor-drug.htm http://www.wikidoc.org/index.php/Simvastatin

Simvastatin is a HMG-CoA Reductase Inhibitor that is FDA approved for the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It reduces levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL). Common adverse reactions include abdominal pain, constipation, nausea, headache, upper respiratory infection. Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid-modifying doses ( ≥ 1 g/day niacin) of niacin-containing products. The risk of myopathy, including rhabdomyolysis, is increased by concomitant administration of amiodarone, dronedarone, ranolazine, or calcium channel blockers such as verapamil, diltiazem, or amlodipine.

CNS Activity

Originator

Merck
231
Curator's Comment: # Merck & Co., Inc.

Approval Year

1991
113
Targets

Targets

Primary TargetPharmacologyConditionPotency
Substrate
643
Inhibitor
8146
 4.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8307
ZOCOR

Approved Use

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets, USP can be started simultaneously with diet. Simvastatin tablets, USP are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. (1.1) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. (1.2) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbeta­lipoproteinemia. (1.2) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. (1.2) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. (1.2, 1.3) Limitations of Use Simvastatin tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. (1.4) 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: 1. LDL cholesterol remains ≥190 mg/dL; or 2. LDL cholesterol remains ≥160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C <130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V).

Launch Date

6.9344638E11
Primary
Approved
8307
ZOCOR

Approved Use

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets, USP can be started simultaneously with diet. Simvastatin tablets, USP are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. (1.1) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. (1.2) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbeta­lipoproteinemia. (1.2) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. (1.2) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. (1.2, 1.3) Limitations of Use Simvastatin tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. (1.4) 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: 1. LDL cholesterol remains ≥190 mg/dL; or 2. LDL cholesterol remains ≥160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C <130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V).

Launch Date

6.9344638E11
Primary
Approved
8307
ZOCOR

Approved Use

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets, USP can be started simultaneously with diet. Simvastatin tablets, USP are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. (1.1) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. (1.2) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbeta­lipoproteinemia. (1.2) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. (1.2) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. (1.2, 1.3) Limitations of Use Simvastatin tablets, USP have not been studied in Fredrickson Types I and V dyslipidemias. (1.4) 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: 1. LDL cholesterol remains ≥190 mg/dL; or 2. LDL cholesterol remains ≥160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C <130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V).

Launch Date

6.9344638E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
54.711 ng/mL
REVIEW
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206679Orig1s000ClinPharmR.pdf
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMVASTATIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.006 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01979185
20 mg single, oral
dose: 20 mg
route of administration: oral
experiment type: single
co-administered:
SIMVASTATIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
6.85 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01960140
40 mg single, oral
dose: 40 mg
route of administration: oral
experiment type: single
co-administered:
SIMVASTATIN plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.93 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01960140
40 mg single, oral
dose: 40 mg
route of administration: oral
experiment type: single
co-administered:
TENIVASTATIN plasma
Homo sapiens
population: healthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
235.795 ng × h/mL
REVIEW
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206679Orig1s000ClinPharmR.pdf
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMVASTATIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
34.3509999999999 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01979185
20 mg single, oral
dose: 20 mg
route of administration: oral
experiment type: single
co-administered:
SIMVASTATIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
38.142 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT01979185
20 mg single, oral
dose: 20 mg
route of administration: oral
experiment type: single
co-administered:
SIMVASTATIN plasma
Homo sapiens
population: healthy
age: Adults
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.87 h
REVIEW
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206679Orig1s000ClinPharmR.pdf
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMVASTATIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670

inhibitor
1532
substrate
985

inhibitor
1695
substrate
1168

inhibitor
1789
inhibitor
1570

OverviewOther

Other InhibitorOther SubstrateOther Inducer
BSEP
392

CYP2C8
869

CYP2C19
1410

P-gp
1401
CYP3A5
383

CYP2A6
510

CYP2C8
670

CYP2C19
955

CYP1A2
1013

CYP2E1
633

OATP2
6

OATP1B1
389

OATP1B3
333
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1857
 moderate [Ki 10 uM]
CYP2C8
923
 moderate [Ki 7.1 uM]
CYP2C9
1747
 moderate
CYP2D6
1826
 moderate
CYP2C19
1484
 no
P-gp
1588
 yes [IC50 9 uM]
BSEP
393
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1670
 major
yes (co-administration study)
Comment: cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4
CYP3A5
383
 minor
CYP1A2
1013
 no
CYP2A6
510
 no
CYP2C19
955
 no
CYP2C8
670
 no
CYP2C9
985
 no
CYP2D6
1168
 no
CYP2E1
633
 no
OATP1B3
333
 yes
OATP2
6
 yes
OATP1B1
389
 yes
yes (co-administration study)
Comment: Administered with cyclosporine: AUC of Simvastatin increased 2.6 fold
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1603
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:9150
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9150
MolPort
MolPort-002-507-345
https://www.molport.com/shop/molecule-link/MolPort-002-507-345
Selleck Chemicals
Simvastatin(Zocor)
http://www.selleckchem.com/products/Simvastatin(Zocor).html
ZINC
ZINC000003780893
http://zinc15.docking.org/substances/ZINC000003780893
eMolecules
11021557
https://www.emolecules.com/cgi-bin/more?vid=11021557
eMolecules
2724261
https://www.emolecules.com/cgi-bin/more?vid=2724261
eMolecules
36754543
https://www.emolecules.com/cgi-bin/more?vid=36754543
PubMed

PubMed

TitleDatePubMed
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
2001
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice.
2001 Apr
A new simvastatin (mevinolin)-resistance marker from Haloarcula hispanica and a new Haloferax volcanii strain cured of plasmid pHV2.
2001 Apr
Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis.
2001 Apr
LpAI in HDL subfractions: serum levels in men and women with coronary heart disease and changes under hypolipemic therapy.
2001 Apr
Rhabdomyolysis due to simvastatin in a transplant patient: Are some statins safer than others?
2001 Apr
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
2001 Apr
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.
2001 Apr 1
Differential effect of simvastatin on various signal transduction intermediates in cultured human smooth muscle cells.
2001 Apr 15
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
2001 Apr 17
Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.
2001 Feb
Clinical relevance of statins: their role in secondary prevention.
2001 Feb
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
2001 Feb
The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects.
2001 Feb
Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels.
2001 Feb
[Statins: intervention studies, facts and perspectives].
2001 Feb
Do HMG-CoA reductase inhibitors affect fibrinogen?
2001 Feb
Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia.
2001 Feb
Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis?
2001 Feb 15
Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study.
2001 Feb-Mar
Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis.
2001 Jan
Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs.
2001 Jan
[Antioxidative effects of fluvastatin, and its major metabolites [II]].
2001 Jan
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
2001 Jan
How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?
2001 Jan
Effective use of statins to prevent coronary heart disease.
2001 Jan 15
[The role of HDL in the prevention of cardiovascular events].
2001 Jan 21
The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells.
2001 Jan 27
[Influence of FH Valencia 1 and 2 mutations of the LDL receptor gene on the response to simvastatin in subjects with molecularly defined heterozygous familial hypercholesterolemia in Spain].
2001 Jan 27
[Treatment with statins for the reduction of cardiovascular risk].
2001 Mar
High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia.
2001 Mar
Statin-fibrate combinations in patients with combined hyperlipedemia.
2001 Mar
Statin therapy--what now?
2001 Mar
The influence of short-term treatment with simvastatin on the inflammatory profile of patients with hypercholesterolaemia.
2001 Mar
Effect of simvastatin on vascular smooth muscle responsiveness: involvement of Ca(2+) homeostasis.
2001 Mar
Making the most of cholesterol-lowering margarines.
2001 Mar
Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration.
2001 Mar
HMG-CoA reductase inhibitors and P-glycoprotein modulation.
2001 Mar
Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
2001 Mar
Simvastatin improves arterial compliance in the lower limb but not in the aorta.
2001 Mar
Effects of simvastatin treatment on sICAM-1 and sE-selectin levels in hypercholesterolemic subjects.
2001 Mar
A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.
2001 Mar
Effect of simvastatin in preventing progression of carotid artery stenosis.
2001 Mar 1
Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators.
2001 Mar 1
Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells.
2001 Mar 2
Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management.
2001 Mar 8
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
2001 Mar 8
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
2001 May
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors block calcium-dependent tyrosine kinase Pyk2 activation by angiotensin II in vascular endothelial cells. involvement of geranylgeranylation of small G protein Rap1.
2001 May 11
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
2001 Spring
Patents

Patents

07175854
24
EP 33538
1
JP2001507331A
1
JP2002145770A
1
JP2002501887A
9
JP2002543189A
2
JP2003515526A
454
JP2005200419A
1
JP2006335658A
4
JP2006512417A
5
JP2006521825A
2
JP2007500677A
16
JP2007529285A
11
JP2008539832A
75
JP2009235105A
2
JP2009511496A
2
JP2009521905A
2
JP2009536078A
2
JP2010090094A
8
JP2010150288A
2
JP2011510067A
50
JP2011524897A
4
JP2011525181A
3
JP2011529067A
28
JP4078300B2
1
JP4708327B2
43
JP4832303B2
9
JP4833840B2
15
JPH0334934A
2
US 4444784
1

Sample Use Guides

In Vivo Use Guide
Dose range is 5 to 40 mg/day. Recommended usual starting dose is 10 or 20 mg once a day in the evening (for patients at high risk of Coronary heart defect is 40 mg/day). Due to the increased risk of myopathy, including rhabdomyolysis, use of the 80-mg dose of Simvastatin should be restricted to patients who have been taking simvastatin 80 mg chronically (e.g., for 12 months or more) without evidence of muscle toxicity.
Route of Administration: Oral
In Vitro Use Guide
Simvastatin (30 μM) significantly (P <0.01) inhibited the proliferative effect of H2O2 (0.5 mM) and its stimulatory actions on ERK1/2 phosphorylation, NF-κB activation and IL-8 production.
Substance Class Chemical
Created
by admin
on Sun Dec 18 20:17:24 UTC 2022
Edited
by admin
on Sun Dec 18 20:17:24 UTC 2022
Record UNII
AGG2FN16EV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SIMVASTATIN
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
SIMVASTATIN [MI]
Common Name English
SIMVASTATIN [JAN]
Common Name English
MK-0733
Code English
ZOCOR
Brand Name English
simvastatin [INN]
Common Name English
SIMVASTATIN COMPONENT OF SIMCOR
Common Name English
SIMVASTATIN [EP MONOGRAPH]
Common Name English
C10AA01
Code English
SIMCOR COMPONENT SIMVASTATIN
Common Name English
SIMVASTATIN [MART.]
Common Name English
SIMVASTATIN [USP MONOGRAPH]
Common Name English
SYNVINOLIN
Common Name English
SIMVASTATIN [ORANGE BOOK]
Common Name English
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one
Common Name English
VYTORIN COMPONENT SIMVASTATIN
Common Name English
NSC-758706
Code English
SIMVASTATIN [VANDF]
Common Name English
MK-733
Code English
SIMVASTATIN [HSDB]
Common Name English
Simvastatin [WHO-DD]
Common Name English
SIMVASTATIN [USAN]
Common Name English
POLYCAP COMPONENT SIMVASTATIN
Brand Name English
BUTANOIC ACID, 2,2-DIMETHYL-, 1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER, (1S-(1.ALPHA.,3.ALPHA.,7.BETA.,8.BETA.(2S*,4S*),8A.BETA.))-
Common Name English
SIMVASTATIN [USP-RS]
Common Name English
SIMVASTATIN COMPONENT OF VYTORIN
Common Name English
Classification Tree Code System Code
WHO-ATC C10BX04
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
WHO-ATC C10BA04
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
WHO-VATC QC10BA04
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
NCI_THESAURUS C1655
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
WHO-ATC A10BH51
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
NDF-RT N0000175589
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
LIVERTOX NBK548720
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
WHO-VATC QC10BA02
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
WHO-VATC QC10AA01
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
WHO-VATC QA10BH51
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
WHO-ATC C10BA02
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
NDF-RT N0000000121
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
WHO-ATC C10AA01
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
WHO-VATC QC10BX01
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
WHO-ATC C10BX01
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 12.6
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
WHO-VATC QC10BX04
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
Code System Code Type Description
DAILYMED
AGG2FN16EV
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
EPA CompTox
DTXSID0023581
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
HSDB
7208
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
LACTMED
Simvastatin
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
ChEMBL
CHEMBL1064
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
NCI_THESAURUS
C29454
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
USAN
Y-41
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
PRIMARY
INN
6147
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
RS_ITEM_NUM
1612700
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
PRIMARY
MERCK INDEX
M9947
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY Merck Index
MESH
D019821
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
CHEBI
9150
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
CAS
79902-63-9
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
WIKIPEDIA
SIMVASTATIN
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
PRIMARY
DRUG BANK
DB00641
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
EVMPD
SUB10529MIG
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
DRUG CENTRAL
2445
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
FDA UNII
AGG2FN16EV
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
PUBCHEM
54454
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
PRIMARY
RXCUI
36567
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
PRIMARY RxNorm
NSC
758706
Created by admin on Sun Dec 18 20:17:27 UTC 2022 , Edited by admin on Sun Dec 18 20:17:27 UTC 2022
PRIMARY
IUPHAR
2955
Created by admin on Sun Dec 18 20:17:26 UTC 2022 , Edited by admin on Sun Dec 18 20:17:26 UTC 2022
PRIMARY
Related Record Type Details
3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE
TARGET -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
Structure of SIMVASTATIN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
OCT-1
TRANSPORTER -> INHIBITOR
OATP1B1
TRANSPORTER -> SUBSTRATE
OATP-B
TRANSPORTER -> INHIBITOR
SUBSTRATE USED: ESTRONE-3-SULFATE
Structure of SIMVASTATIN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
OAT-3
TRANSPORTER -> INHIBITOR
OAT-1
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of 6-HYDROXYSIMVASTATIN, (6S)-
METABOLITE ACTIVE -> PARENT
Structure of Dimebutic Acid
METABOLITE -> PARENT
PLASMA
Structure of TENIVASTATIN
METABOLITE ACTIVE -> PRODRUG
MAJOR
Structure of 6-EXOMETHYLENESIMVASTATIN
METABOLITE ACTIVE -> PARENT
MAJOR
Structure of 3-HYDROXYSIMVASTATIN
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
Structure of SIMVASTATIN DIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of TENIVASTATIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LOVASTATIN
IMPURITY -> PARENT
sum of impurities E and F: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of SIMVASTATIN DIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of METHYLENE SIMVASTATIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of TENIVASTATIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of EPILOVASTATIN
IMPURITY -> PARENT
sum of impurities E and F: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYLENE SIMVASTATIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LOVASTATIN
IMPURITY -> PARENT
Epilovastatin and Lovastatin 1.0%
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of EPILOVASTATIN
IMPURITY -> PARENT
Epilovastatin and Lovastatin 1.0%
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ACETYL SIMVASTATIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ANHYDRO SIMVASTATIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ANHYDRO SIMVASTATIN
IMPURITY -> PARENT
sum of impurities B and C: not more than 1.6 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.8 per cent);
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ACETYL SIMVASTATIN
IMPURITY -> PARENT
sum of impurities B and C: not more than 1.6 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.8 per cent);
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of SIMVASTATIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC SIMVASTATIN ACID
PHARMACOKINETIC
Tmax PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966